<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update</h1>

    <table>
      <tr><th>Ticker</th><td>MYNZ</td></tr>
      <tr><th>Float</th><td>8.3 M</td></tr>
      <tr><th>IO</th><td>8.20%</td></tr>
      <tr><th>MC</th><td>7.2 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Mainz Biomed N.V. (NASDAQ: MYNZ) announced a $6.0 million private placement with investor David Lazar via issuance of Convertible Non-Redeemable Preferred Stock, to be completed in two $3.0 million tranches. The first $3.0 million tranche closed on February 13, 2026; the second tranche is expected after required stockholder approvals and prior to April 15, 2026. Net proceeds are designated to fund operations, address outstanding liabilities and preserve operating capability while the company pursues strategic initiatives. David Lazar was named Chairman of the Board. Mainz Biomed said it will refocus on its U.S. pancreatic cancer screening program (PancAlert), evaluate sale of its colorectal cancer screening assets (ColoAlert), and wind down its German subsidiary. The company filed a Form 8-K on February 17, 2026 with details of the transactions.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>First $3.0M tranche of the $6.0M private placement closed on February 13, 2026.</li><li>Financing structured as Convertible Non-Redeemable Preferred Stock provides immediate liquidity.</li><li>David Lazar named Chairman of the Board, aligning investor with governance.</li><li>Proceeds intended to fund operations, address liabilities, and extend runway.</li><li>Strategic focus on U.S. pancreatic cancer screening program and potential asset sales to reduce expenses.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Second $3.0M tranche is contingent on stockholder approvals and not yet closed.</li><li>Company is winding down its German subsidiary.</li><li>Company is seeking to sell colorectal cancer screening assets, indicating restructuring of core operations.</li><li>Issuance of convertible preferred stock may dilute existing common shareholders.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/12116516-0fdf-4554-9054-75996061eb9c" target="_blank">Original Article</a>
    </div>

    <div class="small">MYNZ â€¢ TradersLink AI News</div>
  </div>
</body>
</html>